Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03387111 · ClinicalTrials.gov registry record · Phase 1
QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed
A Phase 1 study, sponsored by ImmunityBio.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT03387111 is a Phase 1 study that was terminated before completion, run by ImmunityBio. The registered enrollment target is 4 participants.
The verdict
NCT03387111, a Phase 1 study, was terminated before completion, sponsored by ImmunityBio.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with SCC who have progressed on or after previous platinum-based chemotherapy and anti-PD-1/PD-L1 therapy. Phase 2 will be based on Simon's two-stage optimal design.
Interventions
- DRUG Aldoxorubicin HCl
- BIOLOGICAL ETBX-011
- BIOLOGICAL ETBX-021
- BIOLOGICAL ETBX-051
- BIOLOGICAL ETBX-061
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2018-01-09 |
| Est. Completion | 2021-01-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03387111
The ClinicalTrials.gov registry entry for NCT03387111 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmunityBio, which has 46 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Aldoxorubicin HCl is the first listed.
NCT03387111 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03387111 about?
NCT03387111 is a clinical study titled "QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed". This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with SCC who have progressed on or after previous platinum-based chemotherapy and anti-PD-1/PD-L1 therapy. Phase 2 will be based on Simon's two-stage optimal design.
What is the current status of trial NCT03387111?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2018-01-09. Estimated completion is 2021-01-11.
What interventions are being tested in trial NCT03387111?
The interventions under investigation include: Aldoxorubicin HCl (DRUG), ETBX-011 (BIOLOGICAL), ETBX-021 (BIOLOGICAL), ETBX-051 (BIOLOGICAL), ETBX-061 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03387111?
This trial is sponsored by ImmunityBio, which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.